Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE versus U GENCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE versus U GENCIN.
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE vs U-GENCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and cell death. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
1-2 drops of ophthalmic solution (neomycin 3.5 mg/mL and dexamethasone 1 mg/mL) or ointment (neomycin 3.5 mg/g and dexamethasone 1 mg/g) into the affected eye(s) every 4-6 hours; in severe cases, every 1-2 hours initially and tapered. For otic use: 3-4 drops into the affected ear(s) 3-4 times daily. Topical: apply thin layer to affected area 1-3 times daily.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
None Documented
None Documented
Neomycin: 2-3 h (topical/ophthalmic absorption minimal; if significant, prolonged in renal impairment). Dexamethasone: 4-6 h (ophthalmic, systemic if absorbed).
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Renal: neomycin ~30-80% unchanged; dexamethasone phosphate ~80% as free/free glucuronide metabolites. Fecal: negligible.
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic